Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4004)
All Articles published online
|
Publishing Process of This Article
|
Nov 10, 2013 (publication date) through Apr 27, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Hirsh V. Are the data on quality of life and patient reported outcomes from clinical trials of metastatic non-small-cell lung cancer important? World J Clin Oncol 2013; 4(4): 82-84 [PMID: 24926427 DOI: 10.5306/wjco.v4.i4.82] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v4/i4/82.htm |
| Number | Citing Articles |
| 1 |
Theocharis Konstantinidis, Chrysi Fragkioudaki, Evridiki Patelarou, Michail Zografakis-Sfakianakis, Symeon Naoum, Ioanna Tsatsou, Ioannis Kalemikerakis, Ourania Govina. Nutritional assessment and quality of life in patients with non-small cell lung cancer undergoing immunotherapy. International Journal of Palliative Nursing 2023; 29(3): 118 doi: 10.12968/ijpn.2023.29.3.118
|
| 2 |
Vera Hirsh. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib. BioDrugs 2015; 29(3): 167 doi: 10.1007/s40259-015-0130-9
|
| 3 |
Sami Morin-Ben Abdallah, Vera Hirsh. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib. Frontiers in Oncology 2017; 7 doi: 10.3389/fonc.2017.00097
|
| 4 |
Santiago Ponce Aix, Denis Talbot, Ramaswamy Govindan, Manuel Cobo Dols, Pieter E Postmus, Conrad Lewanski, Jaafar Bennouna, Juergen R Fischer, Oscar Juan-Vidal, David J Stewart, Andrea Ardizzoni, Rafia Bhore, Marianne Wolfsteiner, Martin Reck, Teng Jin Ong, Daniel Morgensztern. Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer. Future Oncology 2020; 16(12): 749 doi: 10.2217/fon-2019-0796
|
| 5 |
Iftekhar Khan, Zahid Bashir, Martin Forster. Interpreting small treatment differences from quality of life data in cancer trials: an alternative measure of treatment benefit and effect size for the EORTC-QLQ-C30. Health and Quality of Life Outcomes 2015; 13(1) doi: 10.1186/s12955-015-0374-6
|
| 6 |
Mark Boye, Xin Wang, Vichien Srimuninnimit, Jin Hyoung Kang, Chun-Ming Tsai, Mauro Orlando, Tarun Puri, Jong Seok Kim, Narayan Rajan, James Chih-Hsin Yang. First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial. Clinical Lung Cancer 2016; 17(2): 150 doi: 10.1016/j.cllc.2015.12.004
|
| 7 |
Gail Adorno, Cara Wallace. Preparation for the end of life and life completion during late-stage lung cancer: An exploratory analysis. Palliative and Supportive Care 2017; 15(5): 554 doi: 10.1017/S1478951516001012
|
| 8 |
Solange Peters, Alice T. Shaw, Benjamin Besse, Enriqueta Felip, Benjamin J. Solomon, Ross A. Soo, Alessandra Bearz, Shirish M. Gadgeel, Chia-Chi Lin, Steven Kao, Takashi Seto, Elizabeth T. Masters, Antonello Abbattista, Jill S. Clancy, Holger Thurm, Arlene Reisman, Gerson Peltz, D. Ross Camidge. Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. Lung Cancer 2020; 144: 10 doi: 10.1016/j.lungcan.2020.02.011
|
| 9 |
Enriqueta Felip, Vera Hirsh, Sanjay Popat, Manuel Cobo, Andrea Fülöp, Charles Dayen, José M. Trigo, Richard Gregg, Cornelius F. Waller, Jean-Charles Soria, Glenwood D. Goss, James Gordon, Bushi Wang, Michael Palmer, Eva Ehrnrooth, Shirish M. Gadgeel. Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy. Clinical Lung Cancer 2018; 19(1): 74 doi: 10.1016/j.cllc.2017.06.002
|